SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Sunesis Pharmaceuticals, Inc.

395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650-266-3500
http://www.sunesis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees37

Key Executives

NameTitlePayExercisedAge
Mr. Daniel N. Swisher Jr.Chief Exec. Officer, Pres and Director771.59kN/A54
Mr. Gene C. JamiesonVP of Technical OperationsN/AN/AN/A
Dr. Judith A. Fox Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Deborah A. Thomas Ph.D.Sr. VP of Regulatory Affairs, Quality Assurance & Non-Clinical Devel.N/AN/AN/A
Mr. Parvinder S. HyareVP of Global Oncology OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton’s tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

Sunesis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.